A study by Avraham T et al. and Mehrara BJ et al. revealed that the inhibition of Th2 differentiation with IL-4- or IL-13-blocking agents, such as neutralizing antibodies, significantly relieved the symptoms of secondary lymphedema (Avraham et al., 2013; Mehrara et al., 2021). The gene discussed is IL13; the disease is lymphedema.